Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01316692 · ClinicalTrials.gov registry record · Phase 2
Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma
A Phase 2 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT01316692 is a Phase 2 study that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 12 participants.
The verdict
NCT01316692, a Phase 2 study, was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
RATIONALE: Aurora A kinase inhibitor MLN8237 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well Aurora A kinase inhibitor MLN8237 works in treating patients with unresectable stage III-IV melanoma Funding Source - FDA OOPD
Interventions
- PROCEDURE biopsy
- OTHER mass spectrometry
- GENETIC TdT-mediated dUTP nick end labeling assay
- OTHER laboratory biomarker identification and analysis
- OTHER immunohistochemistry/tissue microarrays
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-10 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01316692
The ClinicalTrials.gov registry entry for NCT01316692 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which biopsy is the first listed.
NCT01316692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01316692 about?
NCT01316692 is a clinical study titled "Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma". RATIONALE: Aurora A kinase inhibitor MLN8237 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well Aurora A kinase inhibitor MLN8237 works in treating patients with unresectable stage III-IV melanoma Funding Sou...
What is the current status of trial NCT01316692?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2011-10. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01316692?
The interventions under investigation include: biopsy (PROCEDURE), mass spectrometry (OTHER), TdT-mediated dUTP nick end labeling assay (GENETIC), laboratory biomarker identification and analysis (OTHER), immunohistochemistry/tissue microarrays (OTHER).
Who is sponsoring clinical trial NCT01316692?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.